Dana Rathkopf

University Of Wisconsin-Madison

$340,687

Attributed

$1,362,748

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $363.5K · FY2021–25

$500K$375K$250K$125K$0

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$1,362,748 · 2

By mechanism

UH3$1,011,140 · 1

UH2$351,608 · 1

Top collaborators

Most similar at University Of Wisconsin-Madison

Same institution · by research overlap

Joshua Michael Lang$8,279,603
David J Beebe$20,083,426
Xin Huang$4,106,913
Douglas G McNeel$9,457,366
Scott M Berry$6,162,635

Others in their field

Other Emerging Leaders on “Cancer Patient”

Leonard Freedman · Leidos Biomedical Research, Inc.$268,085,841
Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$143,792,984
Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
Martha Hering · Westat, Inc.$57,098,843
Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
Nancy Roche · Leidos Biomedical Research, Inc.$39,999,252

Research focus

Cancer PatientCentrifugationAdenocarcinomaAbirateroneCellsCellular AssayAndrogen ReceptorAppearanceAdvanced Prostate CancerAr GeneAftercareCategoriesBiological MarkersAcetatesBiomedical EngineeringBiopsyBloodBlood CellsAreaBoneCancer BiomarkersCancer CellCancer CenterChemotherapy

Grant awards (5)

Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$328,747

UH3 · FY2025 · CA

Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$318,930

UH3 · FY2024 · CA

Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$363,463

UH3 · FY2023 · CA

Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$160,240

UH2 · FY2022 · CA

Validation of predictive liquid biomarkers for patients with metastatic prostate cancer$191,368

UH2 · FY2021 · CA